Integra LifeSciences Holdings Corporation
Description
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
About
CEO
Ms. Mojdeh Poul
Employees
3,946
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Devices
MIC code
XNGS
Address
1100 Campus Road, Princeton, NJ 08540, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 3, 2025 | — | — | — | — |
| Jul 28, 2025 | — | — | — | — |
| May 5, 2025 | — | — | — | — |
| Feb 26, 2025 | 0.86 | — | — | — |
| Nov 4, 2024 | 0.39 | 0.41 | 0.02 | 5.13% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 7 | — | 12 |
| Average estimate | — | 0.56 | — | 2.51 |
| Low estimate | — | 0.48 | — | 2.42 |
| High estimate | — | 0.61 | — | 2.63 |
| Last year EPS | — | 0.55 | — | 2.45 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-3.990%
Next qtr. (Mar 2025)
2.220%
Current year
-20.930%
Next year (Dec 2025)
2.570%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 1.54B | 1.56B | 1.54B | 1.37B | 1.52B |
| Cost of revenue | 656.84M | 587.36M | 597.81M | 520.83M | 564.68M |
| Gross profit | 884.74M | 970.31M | 944.64M | 851.03M | 952.88M |
| Operating expense | |||||
| Research & development | 104.19M | 101.19M | 93.05M | 77.38M | 79.57M |
| Selling general and admin | 656.64M | 616.32M | 637.45M | 594.53M | 687.60M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 111.53M | 238.92M | 197.23M | 151.37M | 158.68M |
| Non operating interest income | |||||
| Income | 17.20M | 11.92M | 6.74M | 9.30M | 10.78M |
| Expense | 51.38M | 49.59M | 50.40M | 71.58M | 53.96M |
| Other income expense | 3.72M | 12.65M | 61.11M | 4.43M | -55.39M |
| Pretax income | 81.07M | 213.89M | 214.68M | 93.52M | 60.10M |
| Tax provision | 13.33M | 33.34M | 45.60M | -40.37M | 9.90M |
| Net income | 67.74M | 180.55M | 169.08M | 133.89M | 50.20M |
| Basic EPS | 0.87 | 2.16 | 2.00 | 1.59 | 0.58 |
| Diluted EPS | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 |
| Basic average shares | 78.17M | 83.59M | 84.70M | 84.34M | 85.87M |
| Diluted average shares | 78.17M | 83.59M | 84.70M | 84.34M | 85.87M |
| EBITDA | 255.96M | 381.14M | 343.11M | 281.13M | 288.44M |
| Net income from continuing op. | 67.74M | 180.55M | 169.08M | 133.89M | 50.20M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3.78B | 3.89B | 3.78B | 3.62B | 3.30B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 276.40M | 456.66M | 513.45M | 470.17M | 198.91M |
| Other short term investments | 32.69M | — | — | — | — |
| Accounts receivable | 259.33M | 263.47M | 231.83M | 225.53M | 275.30M |
| Other receivables | — | — | — | — | — |
| Inventory | 389.61M | 324.58M | 317.39M | 310.12M | 316.05M |
| Prepaid assets | 67.36M | 85.76M | 91.05M | 69.28M | 67.91M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | 162.11M | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 32.64M | 31.03M | 91.05M | 69.28M | 67.91M |
| Non current assets | |||||
| Properties | 160.08M | 152.08M | 87.33M | 84.80M | 127.63M |
| Land and improvements | 978,000 | 966,000 | 1.51M | 1.54M | 1.48M |
| Machinery furniture equipment | 379.58M | 354.35M | 352.90M | 331.59M | 315.86M |
| Construction in progress | 137.28M | 103.88M | 94.85M | 73.89M | 140.37M |
| Leases | 171.06M | 163.34M | 155.50M | 144.85M | 114.94M |
| Accumulated depreciation | -367.45M | -329.73M | -314.87M | -282.85M | -284.60M |
| Goodwill | 3.18B | 3.20B | 3.17B | 2.85B | 2.94B |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 1.07B | 1.13B | 1.15B | 989.44M | 1.03B |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 104.27M | 103.18M | 73.39M | 84.97M | 27.27M |
| Total liabilities | 2.19B | 2.09B | 2.10B | 2.10B | 1.89B |
| Current liabilities | |||||
| Accounts payable | 92.33M | 102.10M | 61.84M | 54.61M | 113.09M |
| Accrued expenses | 100.84M | 80.03M | 120.46M | 94.19M | 76.81M |
| Short term debt | 29.82M | 52.75M | 59.78M | 159.07M | 57.25M |
| Deferred revenue | 8.54M | 7.25M | 5.30M | 5.28M | 4.77M |
| Tax payable | — | — | — | — | — |
| Pensions | 75.46M | 78.77M | 92.66M | 76.12M | 79.39M |
| Other current liabilities | — | — | — | 11.75M | — |
| Non current liabilities | |||||
| Long term debt | 1.65B | 1.56B | 1.59B | 1.50B | 1.40B |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 35.32M | 63.34M | 45.79M | 16.19M | 36.55M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 199.94M | 138.50M | 120.26M | 186.73M | 118.08M |
| Shareholders equity | |||||
| Common stock | 909,000 | 905,000 | 896,000 | 893,000 | 887,000 |
| Retained earnings | 946.86M | 879.12M | 698.57M | 532.27M | 398.57M |
| Other shareholders equity | -15.11M | 10.27M | -45.16M | -74.06M | -76.40M |
| Total shareholders equity | 1.59B | 1.80B | 1.68B | 1.51B | 1.42B |
| Additional paid in capital | 1.30B | 1.28B | 1.26B | 1.29B | 1.21B |
| Treasury stock | 647.26M | 362.86M | 234.45M | 235.14M | 119.94M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||
| Net Income | 67.74M | 180.55M | 169.08M | 133.89M | 50.20M | 60.80M | 64.74M | 74.56M | 6.85M | 36.30M | 22.03M | 41.20M | 27.99M | 65.67M | 50.96M | 27.73M | 33.47M | 29.41M | 37.19M | 17.20M | 26.86M | 35.28M | 26.16M | -10.96M | -5.97M | -12.34M | -17.00M | -7.50M | -25.40M |
| Depreciation | 123.51M | 118.30M | 119.84M | 116.03M | 109.46M | 110.73M | 88.95M | 72.67M | 58.86M | 46.43M | 31.01M | 52.61M | 50.17M | 39.17M | 39.69M | 30.72M | 27.04M | 21.48M | 13.22M | 11.59M | 9.04M | 7.16M | 6.26M | 5.18M | 2.81M | 957,000 | 1.80M | 2.00M | 1.40M |
| Deferred Taxes | -11.89M | -4.59M | -2.76M | -64.14M | -19.05M | -8.18M | -67.30M | -6.47M | -351,000 | -6.85M | -1.34M | 1.54M | 1.16M | 4.13M | 548,000 | -33.54M | -12.72M | 3.24M | 9.90M | 6.10M | 12.36M | -13.40M | -12.09M | — | -1.81M | — | — | — | — |
| Stock-Based Compensation | 20.14M | 27.73M | 36.21M | 19.59M | 21.26M | 20.78M | 21.55M | 17.31M | 15.45M | 14.55M | 9.84M | 9.05M | 26.81M | 17.21M | 15.58M | 32.64M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 21.24M | -10.64M | 8.70M | 31.92M | 76.49M | 7.48M | -1.99M | -32.20M | 9.61M | 8.91M | 8.76M | -19.37M | 14.14M | 2.01M | 4.51M | 12.49M | 18.77M | 18.66M | — | — | — | — | — | — | 100,000 | — | -100,000 | 300,000 | 100,000 |
| Accounts Receivable | 4.59M | -33.91M | 7.27M | 52.11M | -9.43M | -17.02M | -89.70M | -17.52M | -16.23M | -17.15M | 1.01M | 3.78M | -1.88M | -3.78M | 21.15M | -23.53M | -2.84M | -26.13M | 491,000 | -13.29M | -4.82M | -2.11M | 98,000 | -3.48M | -510,000 | -287,000 | 100,000 | -1.10M | -200,000 |
| Accounts Payable | -20.23M | 17.34M | 32.87M | -57.51M | 14.67M | 3.59M | 95.32M | -414,000 | 8.21M | 811,000 | 1.33M | -21.07M | -11.84M | 6.74M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -68.59M | -31.47M | -833,000 | -37.54M | -32.82M | 11.25M | 26.86M | -8.21M | -2.07M | -38.29M | -23.64M | -3.25M | -973,000 | -15.54M | 8.39M | 13.30M | -18.11M | 12.42M | -10.21M | -10.98M | -11.85M | 3.76M | -2.79M | -10.38M | 12.28M | 656,000 | 200,000 | -1.20M | -100,000 |
| Operating Cash Flow | 136.53M | 263.31M | 370.37M | 194.35M | 210.78M | 189.42M | 138.43M | 99.73M | 80.34M | 44.72M | 49.01M | 64.49M | 105.57M | 115.60M | 140.82M | 59.79M | 45.61M | 59.07M | 50.59M | 10.63M | 31.59M | 30.69M | 17.64M | -19.64M | 6.91M | -11.02M | -15.00M | -7.50M | -24.20M |
| Investing Activities | |||||||||||||||||||||||||||||
| Capital Expenditures | -66.87M | -31.20M | -48.02M | -35.23M | -69.50M | -77.32M | -43.21M | -47.01M | -31.98M | -38.34M | -41.77M | -69.03M | -38.43M | -37.14M | -25.24M | -13.40M | -22.16M | -10.83M | -8.05M | -8.51M | -3.84M | -2.25M | -2.86M | -1.67M | 4.05M | -1.12M | -600,000 | -900,000 | -2.90M |
| Net Intangibles | — | -4.74M | -58,000 | -25.00M | -65.00M | — | — | — | — | -475,000 | — | — | — | — | -2.33M | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -27.55M | -113.44M | — | -30.51M | 26.70M | -1.20B | 225,000 | -328.89M | -320.92M | -2.98M | -7.28M | -151.95M | -5.18M | -60.78M | -86.87M | -100.81M | -228.66M | -50.60M | -29.30M | -50.41M | -25.02M | -6.35M | -16.19M | -14.94M | — | — | — | — |
| Purchase of Investments | -32.69M | — | — | -7.84M | — | — | — | — | — | — | — | -67.91M | — | — | — | — | — | -13.07M | -65.50M | -190.89M | -217.07M | -39.11M | -88.53M | -13.39M | -14.74M | -23.77M | -37.10M | -41.50M | -1.20M |
| Sale of Investments | 5.38M | 4.91M | 76,000 | — | 1.58M | — | 16.95M | — | — | — | — | 64.94M | — | — | — | — | — | 109.87M | 93.32M | 241.44M | 178.48M | 35.40M | 3.00M | 16.98M | 26.00M | 33.02M | 35.50M | 21.10M | — |
| Investing Cash Flow | -94.18M | -53.84M | -161.39M | -43.07M | -97.67M | -49.71M | -1.22B | -42.62M | -364.95M | -359.26M | -44.75M | -79.28M | -190.38M | -42.32M | -86.02M | -100.28M | -122.97M | -142.70M | -30.84M | 12.74M | -94.34M | -30.98M | -94.74M | -14.50M | 364,000 | 9.25M | -2.20M | -21.30M | 6.10M |
| Financing Activities | |||||||||||||||||||||||||||||
| Long-Term Debt Issuance | 165.10M | 40.75M | 25.50M | 746.50M | 236.90M | 171.20M | 1.31B | 680.00M | 545.00M | 425.00M | 30.00M | 155.00M | 375.00M | 105.00M | — | 260.00M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -110.60M | -148.55M | -125.50M | -441.00M | -246.10M | -660.00M | -117.00M | -696.22M | -468.85M | -195.61M | -165.00M | -147.20M | -213.44M | -88.23M | -178.01M | -119.56M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -13.74M | -24.62M | -5.05M | -29.42M | -6.51M | -51.05M | -30.83M | -9.38M | -55.02M | -5.93M | -783,000 | 3.25M | -7.22M | -3.22M | 20,000 | 1.59M | -55.38M | 1.34M | — | — | — | — | — | 35,000 | — | — | — | — | -100,000 |
| Financing Cash Flow | -234.24M | -257.42M | -105.05M | 176.08M | -15.71M | -190.26M | 1.16B | -25.60M | 240.80M | 223.47M | 16.68M | 11.05M | 70.88M | -17.72M | -177.99M | 153.54M | -121.47M | -52.83M | -46.96M | -8.12M | -21.25M | 1.56M | 123.11M | 13.38M | 12.28M | 3.76M | 400,000 | 36.50M | 1.00M |
| Other Cash Details | |||||||||||||||||||||||||||||
| End Cash Position | 276.40M | 456.66M | 513.45M | 470.17M | 198.91M | 138.84M | 174.94M | 102.06M | 48.13M | 71.99M | 120.61M | 96.94M | 100.81M | 128.76M | 71.89M | 183.55M | 57.34M | 22.70M | 46.89M | 69.86M | 78.98M | 43.58M | 44.52M | 14.09M | 19.30M | 5.28M | 2.10M | — | — |
| Income Tax Paid | 23.60M | 35.90M | 49.50M | 29,800 | 16,200 | 10,400 | 14,600 | 4,300 | 21,300 | 6,800 | 3,700 | 12,700 | 14,500 | — | 20.53M | 41.25M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 44.30M | 42.20M | 43.20M | 47,300 | 48,900 | 58,300 | 32,300 | 57,200 | 12,700 | 10,900 | 9,500 | 12,000 | 13,200 | — | 11.34M | 17.26M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 73.09M | 217.38M | 264.35M | 139.94M | 96.90M | 121.94M | 71.04M | 69.08M | 71.44M | 44.75M | 10.97M | -9.93M | 65.90M | 68.43M | 115.67M | 59.19M | 24.45M | 60.18M | 48.80M | 30.47M | 30.98M | 29.73M | 12.84M | -8.23M | 193,000 | -10.98M | -8.70M | -9.20M | -8.50M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | Nov 30, 2024 | 4,316,650 | 114.61M | 5.59% |
| Undiscovered Managers Behavioral Value Fund | Sep 30, 2024 | 3,445,218 | 91.47M | 4.46% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 2,136,253 | 56.72M | 2.77% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,889,586 | 50.17M | 2.45% |
| Invesco Small Cap Value Fd | Oct 31, 2024 | 1,691,400 | 44.91M | 2.19% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 1,653,071 | 43.89M | 2.14% |
| Smallcap World Fund | Sep 30, 2024 | 1,178,305 | 31.28M | 1.53% |
| Vanguard Small Cap Value Index Fund | Sep 30, 2024 | 1,117,448 | 29.67M | 1.45% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 990,482 | 26.30M | 1.28% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 687,174 | 18.24M | 0.89% |
Article
Notice To Long-Term Integra Lifesciences Holdings Corporation (NASDAQ: IART) Shareholders: Grabar Law Investigates Claims on Your Behalf
PHILADELPHIA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company.
Feb 4, 2025
Article
Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025
PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
Feb 4, 2025
Article
IART vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Jan 22, 2025
